Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered– Hagens Berman
SAN FRANCISCO, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Class Period: Aug. 5, 2021 – Nov. 29, 2023 Lead Plaintiff Deadline: Mar. 19, 2024 Visit: …